What is the drug interaction between ticagrelor and carbamazepine?

Ticagrelor and Carbamazepine: Contraindicated Combination

The combination of ticagrelor and carbamazepine is contraindicated and should be avoided. Carbamazepine is a potent CYP3A4 inducer that dramatically reduces ticagrelor plasma levels, resulting in loss of antiplatelet efficacy and increased risk of thrombotic events.

Mechanism of Interaction

Carbamazepine is a potent inducer of hepatic CYP3A4 (and also CYP1A2, 2B6, 2C8/9/19), which significantly accelerates the metabolism of ticagrelor 1. Since ticagrelor is metabolized predominantly by CYP3A4 2, this induction leads to:

• Substantially decreased ticagrelor plasma concentrations
• Reduced antiplatelet effect
• Dramatically shortened duration of action

Clinical Evidence

Real-world data demonstrates the severity of this interaction: A recent case series showed that in patients taking CYP3A4 inducers (including carbamazepine, phenobarbital, and phenytoin), the antiplatelet effect of ticagrelor was dramatically shortened 3. Specifically:

• Offset of antiplatelet effect occurred in only 10-24 hours (measured by platelet reactivity units)
• This compares to the expected 36-48 hours in patients without enzyme induction
• The rapid return of platelet function creates a high-risk window for thrombotic events

The 2018 European Heart Rhythm Association guidelines explicitly classify strong CYP3A4 inducers as contraindicated (dark brown coding) when used with drugs metabolized by this pathway 4.

Clinical Management Algorithm

If a patient is already taking carbamazepine:

1. Do not initiate ticagrelor - choose an alternative P2Y12 inhibitor
2. Clopidogrel (75 mg daily) is the preferred alternative, as it has no clinically significant interaction with carbamazepine 5, 6
3. Prasugrel may also be considered if appropriate for the clinical scenario (no prior stroke/TIA, age <75 years, weight >60 kg) 7, 8

If a patient on ticagrelor requires carbamazepine:

1. Switch to clopidogrel immediately before initiating carbamazepine
2. Use a 600 mg loading dose of clopidogrel if in the acute phase post-ACS
3. Continue with 75 mg daily maintenance dosing

If ticagrelor was inadvertently given with carbamazepine:

1. Monitor platelet reactivity units (PRU) every 6-12 hours 3
2. When PRU indicates loss of antiplatelet effect (typically within 10-24 hours):
   • Load with clopidogrel 600 mg OR
   • Load with prasugrel 60 mg (if appropriate)
3. Continue with standard maintenance dosing of the chosen alternative

Important Caveats

• This interaction applies to all strong CYP3A4 inducers, including phenytoin, phenobarbital, rifampin, and St. John's wort 4, 1
• The FDA labeling for carbamazepine explicitly states it is a potent CYP3A4 inducer that reduces plasma concentrations of co-medications metabolized by this enzyme 1
• Unlike interactions with statins (which can be managed with dose adjustments 2), the ticagrelor-carbamazepine interaction cannot be safely managed through dose titration due to unpredictable antiplatelet effects

Why Clopidogrel is Safe

Clopidogrel is metabolized primarily by CYP2C19 (not CYP3A4), making it immune to this particular interaction 5, 6. While carbamazepine has minor effects on CYP2C19, these are not clinically significant for clopidogrel efficacy.